

February 22, 1972

Samuel C. Kaim, M.D.
Director, Alcohol & Drug Dependence Service
Veterans Administration
Washington, D.C. 20420

Dear Sam,

I look forward to participating in the 17th annual V.A. Conference in St. Louis next month. At the end of the week, I will have the time to write a summary of my presentation on the panel, and should send it to you next week, well in time for the session.

A short c.v. is enclosed.

For the teaching session, I will prepare a summary of our present treatment approaches, emphasizing the similarities and the differences in using methadone and levomethadyl, and cyclazocine and naloxone; and the relation of these drug regimens to rehabilitation, casework, re-education, counselling, and psychotherapy.

It was kind of you to consider my serving on the steering committee for the collaborative studies in drug abuse, particularly for acetylmethadol. I would be pleased to contribute whatever I can, and hope that my experience may be of assistance. (My paper on 1-alpha-acetylmethadol will appear soon in the J.A.M.A.-- they changed the name of the drug to the new generic 'official' title of *LEVOMETHADYL*.)

My best regards.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry